KevinJamesHorganMD

Clinical Pharmacology, Clinical Informatics

Advisor, Liquid Biosciences, Aliso Viejo, California

Dr. Horgan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
200 Medical 530 420 120 Plz
# 365
Los Angeles, CA 90095
Phone+1 310-794-9718

Fax+1 310-301-8751

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Gastroenterology, 1991 - 1993
Johns Hopkins UniversityResidency, Internal Medicine, 1985 - 1988
University College Cork Faculty of MedicineClass of 1982

PubMed

12 citations
Exposure-Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status
Paul Baverel, Lorin Roskos, Manasa Tatipalli, Nancy Lee, Paul K. Stockman
Clinical and Translational Science. 2019-09-01
12 citations
Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host disease.
Paul J. Martin, Terry Furlong, Scott D. Rowley, Steven A. Pergam, Michele E. Lloid
Biology of Blood and Marrow Transplantation. 2012-06-01
362 citations
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Walter Reinisch, Allan Olson
Gastroenterology. 2009-10-01

Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative ColitisJanuary 3rd, 2019
Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational UpdatesNovember 8th, 2018
Seres Therapeutics Announces Appointment of Kevin Horgan, M.D., as Chief Medical OfficerOctober 22nd, 2018